MIND Technology posted strong Q2 results, but falling backlog, weak guidance, and lowered forecasts drive a bearish outlook.

FedEx posted a Q1 beat and FY26 outlook, but weak volumes, stretched valuation, and structural issues cloud the long-term ...

Replimune received an FDA denial for accelerated approval of RP1+Opdivo in melanoma, with trial concerns outweighing strong data. Read why REPL stock is a hold.

CIK offers a 9% yield with steady income, but premium to NAV, limited growth, and credit risks warrant caution. See why CIK ...

Acuren merges with NV5, creating a top North American testing provider. Current valuation limits significant further upside ...

Alibaba has outperformed the S&P 500 with strong cloud growth and AI momentum, but its rally may have run hot. Read why BABA ...

ET stock is deeply undervalued with strong cash flow, 8%+ yield, and 30% upside potential. Read here for more investment ...

International Consolidated Airlines posts 69.9% EPS growth, gains from fuel cost drop, with stable yet complex finances. Find ...

Alibaba leads with AI and cloud growth, strong cash, and tech investments, trading cheaper than U.S. peers despite risks.

Summit Midstream has restructured, strengthened its customer base, and is set to benefit from rising natural gas demand. See ...

FTI Consulting posted record Q2 in restructuring and comms, but tech weakness and CFO change temper outlook despite strong ...

Bristol Myers Squibb is a strong buy, with a 5.5% yield, growth portfolio, and undervalued shares. See here for more analysis ...